{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:47:14Z","timestamp":1794037634740,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Roche Molecular Systems"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Chlamydia trachomatis<\/jats:italic> (CT) and <jats:italic>Neisseria gonorrhoeae<\/jats:italic> (NG) are the most common notifiable sexually transmitted infections (STIs) in the United States. Because symptoms of these infections often overlap with other urogenital infections, misdiagnosis and incorrect treatment can occur unless appropriate STI diagnostic testing is performed in clinical settings. The objective of this study was to describe STI diagnostic testing and antimicrobial treatment patterns and trends among adolescent and adult men and women with lower genitourinary tract symptoms (LGUTS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed insurance claims data from the IBM\u00ae MarketScan\u00ae Research Databases. Patients included were between 14 and 64\u00a0years old with LGUTS as determined by selected International Classification of Diseases codes between January 2010 and December 2019. Testing of STIs and relevant drug claims were captured, and distribution of testing patterns and drug claims were described.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 23,537,812 episodes with LGUTS (87.4% from women; 12.6% from men) were analyzed from 12,341,154 patients. CT\/NG testing occurred in only 17.6% of all episodes. For episodes where patients received treatment within 2\u00a0weeks of the visit date, 89.3% received treatment within the first 3\u00a0days (likely indicating presumptive treatment), and 77.7% received it on the first day. For women with pelvic inflammatory disease and men with orchitis\/epididymitis and acute prostatitis,\u2009\u2264\u200915% received CT\/NG testing, and around one-half received antibiotic treatment within 3\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study revealed low CT\/NG testing rates, even in patients diagnosed with complications commonly associated with these STIs, along with high levels of potentially inappropriate presumptive treatment. This highlights the need for timely and accurate STI diagnosis in patients with LGUTS to inform appropriate treatment recommendations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08434-2","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T09:01:48Z","timestamp":1689238908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Outpatient sexually transmitted infection testing and treatment patterns in the United States: a real-world database study"],"prefix":"10.1186","volume":"23","author":[{"given":"Rebecca","family":"Lillis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Kuritzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zune","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Arcenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avneet","family":"Hansra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie N.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"8434_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/olq.0000000000001355","volume":"48","author":"KM Kreisel","year":"2021","unstructured":"Kreisel KM, Spicknall IH, Gargano JW, Lewis FMT, Lewis RM, Markowitz LE, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex Transm Dis. 2021;48:208\u201314. https:\/\/doi.org\/10.1097\/olq.0000000000001355.","journal-title":"Sex Transm Dis"},{"key":"8434_CR2","unstructured":"Centers for Disease Control and Prevention. National overview of STDs, 2021. 2023. https:\/\/www.cdc.gov\/std\/statistics\/2021\/overview.htm. Accessed 12 May 2023."},{"key":"8434_CR3","unstructured":"Centers for Disease Control and Prevention. Impact of COVID-19 on STDs. 2022. https:\/\/www.cdc.gov\/std\/statistics\/2020\/impact.htm. Accessed 4 Apr 2023."},{"key":"8434_CR4","doi-asserted-by":"publisher","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1\u2013187. https:\/\/doi.org\/10.15585\/mmwr.rr7004a1.","DOI":"10.15585\/mmwr.rr7004a1"},{"key":"8434_CR5","unstructured":"U.S. Department of Health and Human Services. Sexually transmitted infections national strategic plan for the United States: 2021\u20132025. 2020. https:\/\/www.hhs.gov\/sites\/default\/files\/STI-National-Strategic-Plan-2021-2025.pdf. Accessed 4 Apr 2023."},{"key":"8434_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/jama.2021.23487","volume":"327","author":"S Tuddenham","year":"2022","unstructured":"Tuddenham S, Hamill MM, Ghanem KG. Diagnosis and treatment of sexually transmitted infections: a review. JAMA. 2022;327:161\u201372. https:\/\/doi.org\/10.1001\/jama.2021.23487.","journal-title":"JAMA"},{"key":"8434_CR7","doi-asserted-by":"publisher","unstructured":"Unemo M, Seifert HS, Hook EW 3rd, Hawkes S, Ndowa F, Dillon JR. Gonorrhoea. Nat Rev Dis Primers. 2019;5:79. https:\/\/doi.org\/10.1038\/s41572-019-0128-6.","DOI":"10.1038\/s41572-019-0128-6"},{"key":"8434_CR8","doi-asserted-by":"publisher","unstructured":"Hillier SL, Bernstein KT, Aral S. A review of the challenges and complexities in the diagnosis, etiology, epidemiology, and pathogenesis of pelvic inflammatory disease. J Infect Dis. 2021;224:S23\u201328. https:\/\/doi.org\/10.1093\/infdis\/jiab116.","DOI":"10.1093\/infdis\/jiab116"},{"key":"8434_CR9","first-page":"723","volume":"94","author":"JR McConaghy","year":"2016","unstructured":"McConaghy JR, Panchal B. Epididymitis: an overview. Am Fam Physician. 2016;94:723\u20136.","journal-title":"Am Fam Physician"},{"key":"8434_CR10","doi-asserted-by":"publisher","first-page":"5758387","DOI":"10.1155\/2016\/5758387","volume":"2016","author":"PA Chan","year":"2016","unstructured":"Chan PA, Robinette A, Montgomery M, Almonte A, Cu-Uvin S, Lonks JR, et al. Extragenital infections caused by Chlamydia trachomatis and neisseria gonorrhoeae: a review of the literature. Infect Dis Obstet Gynecol. 2016;2016:5758387. https:\/\/doi.org\/10.1155\/2016\/5758387.","journal-title":"Infect Dis Obstet Gynecol"},{"key":"8434_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12879-015-1029-2","volume":"15","author":"M Unemo","year":"2015","unstructured":"Unemo M. Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364. https:\/\/doi.org\/10.1186\/s12879-015-1029-2.","journal-title":"BMC Infect Dis"},{"key":"8434_CR12","doi-asserted-by":"publisher","unstructured":"St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1911\u201316. https:\/\/doi.org\/10.15585\/mmwr.mm6950a6.","DOI":"10.15585\/mmwr.mm6950a6"},{"key":"8434_CR13","doi-asserted-by":"publisher","unstructured":"Brunham RC, Paavonen J. Reproductive system infections in women: lower genital tract syndromes. Pathog Dis. 2020;78:ftaa022. https:\/\/doi.org\/10.1093\/femspd\/ftaa022.","DOI":"10.1093\/femspd\/ftaa022"},{"key":"8434_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3389\/fimmu.2014.00534","volume":"5","author":"KA Redgrove","year":"2014","unstructured":"Redgrove KA, McLaughlin EA. The role of the immune response in Chlamydia trachomatis infection of the male genital tract: a double-edged sword. Front Immunol. 2014;5:534. https:\/\/doi.org\/10.3389\/fimmu.2014.00534.","journal-title":"Front Immunol"},{"key":"8434_CR15","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.3389\/fmicb.2018.03101","volume":"9","author":"ME Panzetta","year":"2018","unstructured":"Panzetta ME, Valdivia RH, Saka HA. Chlamydia persistence: a survival strategy to evade antimicrobial effects in-vitro and in-vivo. Front Microbiol. 2018;9:3101. https:\/\/doi.org\/10.3389\/fmicb.2018.03101.","journal-title":"Front Microbiol"},{"key":"8434_CR16","doi-asserted-by":"publisher","unstructured":"Behzadi P, Behzadi E, Pawlak-Adamska EA. Urinary tract infections (UTIs) or genital tract infections (GTIs)? It's the diagnostics that count. GMS Hyg Infect Control. 2019;14:Doc14. https:\/\/doi.org\/10.3205\/dgkh000320.","DOI":"10.3205\/dgkh000320"},{"key":"8434_CR17","doi-asserted-by":"publisher","unstructured":"Zeidan AR, Strey K, Vargas MN, Reveles KR. Sexually transmitted infection laboratory testing and education trends in US outpatient physician offices, 2009\u20132016. Fam Med Community Health. 2021;9. https:\/\/doi.org\/10.1136\/fmch-2021-000914.","DOI":"10.1136\/fmch-2021-000914"},{"key":"8434_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s11606-022-07578-2","volume":"37","author":"S Keddem","year":"2022","unstructured":"Keddem S, Maier M, Gardella C, Borgerding J, Lowy E, Chartier M, et al. Gonorrhea and chlamydia testing and case rates among women veterans in the Veterans Health Administration. J Gen Intern Med. 2022;37:706\u201313. https:\/\/doi.org\/10.1007\/s11606-022-07578-2.","journal-title":"J Gen Intern Med"},{"key":"8434_CR19","unstructured":"IBM. MarketScan research databases. 2022. https:\/\/www.ibm.com\/products\/marketscan-research-databases. Accessed 4 Apr 2023."},{"key":"8434_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/MOP.0000000000000578","volume":"30","author":"CL Shannon","year":"2018","unstructured":"Shannon CL, Klausner JD. The growing epidemic of sexually transmitted infections in adolescents: a neglected population. Curr Opin Pediatr. 2018;30:137\u201343. https:\/\/doi.org\/10.1097\/MOP.0000000000000578.","journal-title":"Curr Opin Pediatr"},{"key":"8434_CR21","unstructured":"Centers for Disease Control and Prevention. Preliminary 2021 STD surveillance data. 2021. https:\/\/www.cdc.gov\/std\/statistics\/2021\/. Accessed 4 Apr 2023."},{"key":"8434_CR22","doi-asserted-by":"publisher","first-page":"e3235","DOI":"10.1093\/cid\/ciaa1454","volume":"73","author":"LA Beste","year":"2020","unstructured":"Beste LA, Maier MM, Borgerding J, Lowy E, Hauser RG, Van Epps P, et al. Testing practices and incidence of chlamydial and gonococcal infection in the Veterans Health Administration, 2009\u20132019. Clin Infect Dis. 2020;73:e3235\u201343. https:\/\/doi.org\/10.1093\/cid\/ciaa1454.","journal-title":"Clin Infect Dis"},{"key":"8434_CR23","unstructured":"U.S. Food and Drug Administration. FDA approves safety labeling changes for fluoroquinolones. 2016. https:\/\/www.fda.gov\/drugs\/information-drug-class\/fda-approves-safety-labeling-changes-fluoroquinolones. Accessed 12 May 2022."},{"key":"8434_CR24","first-page":"873","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates\u2013United States, 2000\u20132010. MMWR Morb Mortal Wkly Rep. 2011;60:873\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"8434_CR25","first-page":"590","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. Update to CDC\u2019s Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61:590\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"8434_CR26","doi-asserted-by":"publisher","unstructured":"Gaydos CA, Manabe YC, Melendez JH. A narrative review of where we are with point-of-care sexually transmitted infection testing in the United States. Sex Transm Dis. 2021;48:S71\u20137. https:\/\/doi.org\/10.1097\/olq.0000000000001457.","DOI":"10.1097\/olq.0000000000001457"},{"key":"8434_CR27","unstructured":"Centers for Disease Control and Prevention. CDC fact sheet: information for teens and young adults: staying healthy and preventing STDs. 2022. https:\/\/www.cdc.gov\/std\/life-stages-populations\/stdfact-teens.htm. Accessed 4 Apr 2023."},{"key":"8434_CR28","unstructured":"Centers for Disease Control and Prevention. Tables \u2013 sexually transmitted disease surveillance, 2020. 2022. https:\/\/www.cdc.gov\/std\/statistics\/2020\/tables.htm. Accessed 4 Apr 2023."},{"key":"8434_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6404a1","volume":"64","author":"KA Workowski","year":"2015","unstructured":"Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1\u2013137.","journal-title":"MMWR Recomm Rep"},{"key":"8434_CR30","doi-asserted-by":"publisher","unstructured":"Dixon BE, Rahurkar S, Ho Y, Arno JN. Reliability of administrative data to identify sexually transmitted infections for population health: a systematic review. BMJ Health Care Inform. 2019;26. https:\/\/doi.org\/10.1136\/bmjhci-2019-100074.","DOI":"10.1136\/bmjhci-2019-100074"},{"key":"8434_CR31","doi-asserted-by":"publisher","unstructured":"Benedict K, Lyman M, Jackson BR. Possible misdiagnosis, inappropriate empiric treatment, and opportunities for increased diagnostic testing for patients with vulvovaginal candidiasis-United States, 2018. PLoS One. 2022;17:e0267866. https:\/\/doi.org\/10.1371\/journal.pone.0267866.","DOI":"10.1371\/journal.pone.0267866"},{"key":"8434_CR32","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/sextrans-2019-054358","volume":"96","author":"I Toskin","year":"2020","unstructured":"Toskin I, Govender V, Blondeel K, Murtagh M, Unemo M, Zemouri C, et al. Call to action for health systems integration of point-of-care testing to mitigate the transmission and burden of sexually transmitted infections. Sex Transm Infect. 2020;96:342\u20137. https:\/\/doi.org\/10.1136\/sextrans-2019-054358.","journal-title":"Sex Transm Infect"},{"key":"8434_CR33","doi-asserted-by":"publisher","unstructured":"Vanbaelen T, Van Dijck C, Laumen J, Gonzalez N, De Baetselier I, Manoharan-Basil SS, et al. Global epidemiology of antimicrobial resistance in commensal Neisseria species: a systematic review. Int J Med Microbiol. 2022;312:151551. https:\/\/doi.org\/10.1016\/j.ijmm.2022.151551.","DOI":"10.1016\/j.ijmm.2022.151551"},{"key":"8434_CR34","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.5858\/arpa.2020-0118-RA","volume":"144","author":"PC Adamson","year":"2020","unstructured":"Adamson PC, Loeffelholz MJ, Klausner JD. Point-of-care testing for sexually transmitted infections: a review of recent developments. Arch Pathol Lab Med. 2020;144:1344\u201351. https:\/\/doi.org\/10.5858\/arpa.2020-0118-RA.","journal-title":"Arch Pathol Lab Med"},{"key":"8434_CR35","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/olq.0000000000000865","volume":"45","author":"LE Widdice","year":"2018","unstructured":"Widdice LE, Hsieh YH, Silver B, Barnes M, Barnes P, Gaydos CA. Performance of the Atlas genetics rapid test for Chlamydia trachomatis and women\u2019s attitudes toward point-of-care testing. Sex Transm Dis. 2018;45:723\u20137. https:\/\/doi.org\/10.1097\/olq.0000000000000865.","journal-title":"Sex Transm Dis"},{"key":"8434_CR36","unstructured":"Centers for Disease Control and Prevention. STI treatment guidelines, 2021: reporting and confidentiality. 2021. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/clinical-reporting.htm. Accessed 4 Apr 2023."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08434-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08434-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08434-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T09:02:28Z","timestamp":1689238948000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08434-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8434"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08434-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"assertion":[{"value":"13 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data were compliant with the Health Insurance Portability and Accountability Act (HIPAA) of 1996. Research performed in accordance with the Declaration of Helsinki. Institutional review board approval was not required. There is no identifiable information from individuals within these data sets. Consent to participate not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ZH, RA, AH, RS and BY are employees of Roche Molecular Systems and report receiving stocks and stock options from Roche. RL reports receiving funding for this study from Roche, receipt of previous grants for clinical trials from Hologic, Visby, OrthoClinical Diagnostics, Becton Dickinson, Cepheid, Merck and Gilead, as well as previous speakers\u2019 bureau payment and support for meeting attendance from Cepheid and reports participation in a Roche advisory board. SNT reports receiving funding for this study from Roche Molecular Systems, as well as receipt of previous grants from Roche Molecular Systems paid directly to their institution. LK reports receiving consulting fees for this study from Roche Diagnostics, as well as receipt of previous consulting fees and medical writing support from Roche Diagnostics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"469"}}